Please ensure Javascript is enabled for purposes of website accessibility

These 2 Key Themes Are Driving the Stock Market to Record Highs

By Dan Caplinger - Updated Jun 24, 2021 at 4:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out what you need to know about all-time highs for stocks.

Stock market investors remained in a good mood on Thursday, buoyed by prospects for greater government spending and reduced concerns about an overheating economy. As of 1:30 p.m. EDT, the Dow Jones Industrial Average (^DJI 1.27%) had pushed higher by 331 points to 34,205. The S&P 500 (^GSPC 1.73%) had risen 25 points to 4,267, which would represent a new record close, and the Nasdaq Composite's (^IXIC 2.09%) own streak continued with a 90-point gain to 14,362.

Certain themes have helped to support the bull market in stocks for more than a year now, and among today's winners were two stocks that have taken full advantage of favorable conditions in their respective industries. Below, we'll look at why Eli Lilly (LLY 2.63%) and Luminar Technologies (LAZR 9.14%) stood out from the crowd on Thursday as stocks with great prospects for a bright future.

Lilly joins the Alzheimer's fight

Shares of Eli Lilly jumped more than 8% on Thursday. That took the market cap of the drugmaker above the $225 billion mark, and Lilly continued a string of record highs from throughout the past year as it offered good news in the fight against Alzheimer's disease.

Medical professional working with a patient.

Image source: Getty Images.

Lilly got good news from the U.S. Food and Drug Administration on Thursday, with the drugmaker's candidate treatment donanemab gaining the coveted designation as a breakthrough therapy. Donanemab is an experimental drug for treating Alzheimer's, and mid-stage clinical trials have offered some promising results for those hoping for a viable treatment for the disease.

It's important to put the news in context, because competitor Biogen recently gained approval from the FDA for its Alzheimer's drug, Aduhelm. That motivated a change in Lilly's strategy, as it now hopes to take advantage of the expedited process for reviewing study results to seek full FDA approval for donanemab as soon as later this year.

After some skepticism about Biogen's efficacy in treating Alzheimer's, investors seem more comfortable with Lilly's candidate, which has shown signs of slowing cognitive decline among patients. Anything that points toward a potential solution for the millions of people suffering from Alzheimer's is an unqualified positive, and that's why investors are especially excited Thursday.

Luminar lights up

Elsewhere, the electric vehicle industry continued to gain ground, and Luminar Technologies played a key role. The EV technology specialist was up 6% Thursday afternoon after having risen as much as 13% earlier in the day.

Luminar announced that its lidar hardware technology will be standard equipment on the flagship electric vehicle coming from automaker Volvo in the coming year. A fully electric version of the Volvo XC90 is expected to come out in 2022, and the vehicle will feature Luminar's Iris and Sentinel technology. The release also mentioned contributions from NVIDIA and other technology providers, with the overall goal of enhancing safety and reducing accidents and fatalities.

Even with the gains, though, Luminar's stock is still down significantly from its highs earlier in the year. Competition in the EV sensor space is fierce, and some big companies looking to design and manufacture electric vehicles are working hard to come out with their own sensor technology as an alternative to using Luminar as a potential supplier and incorporating its products into their vehicles.

Luminar is a tiny company, and its prospects are still largely speculative. The more big-name customers it can sign, however, the more likely Luminar will be to succeed in the long run.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends NVIDIA. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$308.08 (2.63%) $7.89
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$33,761.05 (1.27%) $424.38
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
$4,280.15 (1.73%) $72.88
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
$13,047.19 (2.09%) $267.27
NVIDIA Corporation Stock Quote
NVIDIA Corporation
$187.09 (4.28%) $7.67
Biogen Inc. Stock Quote
Biogen Inc.
$220.99 (1.27%) $2.77
Luminar Technologies, Inc. Stock Quote
Luminar Technologies, Inc.
$10.99 (9.14%) $0.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.